Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Safety and efficacy of a dermatological intense pulsed light device for the treatment of meibomian gland dysfunction and dry eye syndrome

Poster Details

First Author: M.Ibarz SPAIN

Co Author(s):    A. Corroto   R. Aguejas   J. Rodriguez-Prats              

Abstract Details


To estimate the efficacy of a dermatological intense pulsed light (IPL) device for reducing the signs and symptoms of dry eye disease (DED) in meibomian gland dysfunction (MGD) and to assess patient satisfaction.


Oftalvist Group, Juan Bravo 1, Madrid, Spain


A prospective study that included 30 patients (60 eyes) with MGD and DED was performed with the Ellipse dermatological IPL. At the first visit, the patients filled out the OSDI questionnaire and were tested for osmolarity, tBUT, meibum quality and expressibility and corneal staining (CFS). Patients underwent three treatment sessions, two weeks apart. In each session, 10 pulses were applied on the cheeks (5 per cheek). Parameters were measured at baseline, at the end of the third session and two weeks later. Meibomian gland expression was performed at the end of each session.


OSDI score improved from 49,7419,45 to 20,7115,71 (p<0,05) from baseline to the last visit, osmolarity was higher than 310 mOsm/L in 14 eyes and decreased below the value considered normal in 10 of them. TBUT improved from 4,252,58 to 7,743,17 (p<0,05), reaching values > 10 seconds in 54% of the patients. Meibum quality improved from 2,080,75 (scale 0-3) to 0,890,48 (p<0,05), meibum expresibility from 1,940,87 to 10,39 (p<0,05), and CFS (Oxford Scale 0-5) from 1,961,79 to 0,591,21 (p<0,05). Regarding patient satisfaction, 4 patients did not experience any improvement against 26 that where satisfied or very satisfied with the results.


Ellipse IPL for dermatology is a safe and effective device for the treatment of MGD and DED, that allows to combine ophthalmic and dermatological treatments in the same practice.

Financial Disclosure:


Back to Poster listing